Clinical Trials Browser

Bronchiolitis Obliterans Syndrome × ruxolitinib × Clear all

NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Phase 4 Active not recruiting

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT03774082 2025-12-11

REACH 5

Phase 2 Completed

46 enrolled 21 charts

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT05413356 2022-10-19

Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

Phase 2 Unknown

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms